Serum macrophage-derived chemokine/CCL22 levels are associated with glioma risk, CD4 T cell lymphopenia and survival time
Explore this paper's citation graph
Summary
Circulating CCL22 levels are related to both glioma risk and survival duration independent of age, histology, grade and IDH mutation status, and should be considered a marker of immune status with potential prognostic value.
- Type
- article
- Published
- 2015-02-02
- Cited by
- 44
- References
- 52
- Access
- Open access
- OpenAlex
- https://openalex.org/W1564857641
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:13058123
Keywords
Chemokine, CCL22, Medicine, Immunology, Macrophage
References
- CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011.
- Basic concepts in glioma immunology.
- Impact of genetic targets on primary brain tumor therapy: what's ready for prime time?
- Mechanisms of immune evasion by gliomas.
- Glucocorticoids affect human dendritic cell differentiation and maturation.
- High Cord Blood Levels of the T-Helper 2-Associated Chemokines CCL17 and CCL22 Precede Allergy Development During the First 6 Years of Life
- Phenotypical analysis, relation to malignancy and prognostic relevance of ICOS+T regulatory and dendritic cells in patients with gliomas.
- Comparative analysis of peripheral and localised cytokine secretion in glioblastoma patients.
- Defective Receptor Expression and Dendritic Cell Differentiation of Monocytes in Glioblastomas
- Macrophage-derived Chemokine Is a Functional Ligand for the CC Chemokine Receptor 4*
- Pre-treatment lymphopenia as a prognostic biomarker in colorectal cancer patients receiving chemotherapy
- Targeted knock down of CCL22 and CCL17 by siRNA during DC differentiation and maturation affects the recruitment of T subsets.
- IgE, Allergy, and Risk of Glioma: Update from the San Francisco Bay Area Adult Glioma Study in the Temozolomide Era
- Patients with metastatic breast cancer leading to CD4+ T cell lymphopaenia have poor outcome.
- Immunosuppression in Patients with High Grade Gliomas Treated with Radiation and Temozolomide
- A low frequency variant at 8q24.21 is strongly associated with risk of oligodendroglial tumors and IDH1 or IDH2 mutated astrocytomas
- Immune-Checkpoint Blockade and Active Immunotherapy for Glioma
- Macrophage-derived chemokine (MDC)/CCL22 produced by monocyte derived dendritic cells reflects the disease activity in patients with atopic dermatitis.
- Sustained CD4+ T cell-driven lymphopenia without a compensatory IL-7/IL-15 response among high-grade glioma patients treated with radiation and temozolomide
- CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer
Cited by
- Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites
- A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma.
- Developing immunotherapeutic strategies to target brain tumors
- Chapter 1 - Epidemiology
- Evidence from a large-scale meta-analysis indicates eczema reduces the incidence of glioma
- The effect of Tamoxifen and Fulvestrant on pro-inflammatory markers in oestrogen receptor positive breast cancer
- CCL22-specific T Cells: Modulating the immunosuppressive tumor microenvironment
- MDC and BLC are independently associated with the significant risk of early stage lung adenocarcinoma
- Targeting TGF-β Signaling for Therapeutic Gain.
- Atopic Diseases Correlated with the Incidence of Cancer
- VISUALIZING THE DYNAMICS OF IMMUNE SURVEILLANCE IN BRAIN TUMORS BY INTRAVITAL MULTIPHOTON MICROSCOPY
- Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine
- C-C motif chemokine 22 predicts postoperative prognosis and adjuvant chemotherapeutic benefits in patients with stage II/III gastric cancer
- Maternal Diet, Metabolic State, and Inflammatory Response Exert Unique and Long-Lasting Influences on Offspring Behavior in Non-Human Primates
- Circulating monocytes and tumor-associated macrophages express recombined immunoglobulins in glioblastoma patients
- Discovery of a Potent and Selective CCR4 Antagonist That Inhibits Treg Trafficking into the Tumor Microenvironment.
- Radiotherapy, Lymphopenia, and Host Immune Capacity in Glioblastoma: A Potentially Actionable Toxicity Associated With Reduced Efficacy of Radiotherapy.
- Higher CCL22+ Cell Infiltration is Associated with Poor Prognosis in Cervical Cancer Patients
- Blockade of CD73 delays glioblastoma growth by modulating the immune environment
- Novel Piperidinyl-Azetidines as Potent and Selective CCR4 Antagonists Elicit Antitumor Response as Single Agent and in Combination with Checkpoint Inhibitors.
Related papers
- A transcription factor PU.1 is critical for Ccl22 gene expression in dendritic cells and macrophages
- Expression of macrophage‐derived chemokine (CCL22) in atherosclerosis and regulation by histamine via the H2 receptor
- Molecular characterization and expression analysis of nine CC chemokines in half-smooth tongue sole, Cynoglossus semilaevis.
- Macrophage-derived chemokine CCL22 and regulatory T cells in ovarian cancer patients
- Linked Chromosome 16q13 Chemokines, Macrophage-Derived Chemokine, Fractalkine, and Thymus- and Activation-Regulated Chemokine, Are Expressed in Human Atherosclerotic Lesions
- Cytokines in autoimmune lacrimal gland disease in MRL/MpJ mice.
- A novel expression of macrophage derived chemokine in human bladder cancer.
- An investigation of the inflammatory cytokine and chemokine network in systemic sclerosis
- Reduced chemokine responses in human neonatal cells upon infection with RSV
- Specific allergen immunotherapy: effect on IgE, IgG4 and chemokines in patients with allergic rhinitis